Table 2.

Histomorphology and genetic characterization of murine liver tumors

ModelNo. of tumors (n = 149)No. of dysplastic lesionsMean tumor size (mm)Mutationsa (n = 73)CGH-based similarity to human HCCbP-value CGH matchesCell sizeProliferating tumors
DEN191463 ± 1.4BRAF 3/960.8 (losses)<0.01Small44%
HRAS 1/965.8 (gains)0.636
c-Myc22106.9 ± 3.8CTNNB1 2/1954.1 (losses)<0.01Medium68%
HRAS 1/1957.5 (gains)<0.01
TAK1LPC-KO371182.9 ± 1.7None (0/15)47 (losses)<0.01Large9%
61.8 (gains)<0.01
AlbLTαβ3326.6 ± 3.3None (0/11)53.3 (losses)0.128Large46%
72.3 (gains)<0.01
Mcl-1Δhep38795.6 ± 4.96BRAF 4/1962.8 (losses)<0.01Medium55%
CTNNB1 4/1963.7 (gains)0.113
  • aPutations tested in subset, genes: BRAF, HRAS, CTNNB1, TP53 (exons 5–8), TERT.

  • bPercentages given by synteny analysis of murine tumors (n = 75) and unstratified human HCC cohort (TCGA).